Search results
Showing 46 to 60 of 126 results for nivolumab
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
In development [GID-TA11587] Expected publication date: 25 June 2025
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.
Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.
In development [GID-TA11140] Expected publication date: 23 July 2025
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
Awaiting development [GID-TA11116] Expected publication date: TBC
Find out more about NICE's new proportionate approach to technology appraisals
Find out more about NICE's new proportionate approach to technology appraisals
In development [GID-TA11042] Expected publication date: TBC
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
In development [GID-TA11289] Expected publication date: TBC
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]
Awaiting development [GID-TA11111] Expected publication date: TBC
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies.
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.